Literature DB >> 9374471

The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein.

S Ahmad1, Y M Alsayed, B J Druker, L C Platanias.   

Abstract

Interferon (IFN) alpha induces rapid and transient tyrosine phosphorylation of the Src homology 2/Src homology 3 (SH2/SH3)-containing CrkL adaptor protein in a time- and dose-dependent manner. Such phosphorylation is most likely regulated by the Type I interferon receptor (IFNR)-associated Tyk-2 kinase, as suggested by the detection of Type I IFN-dependent tyrosine kinase activity in anti-CrkL immunoprecipitates and the IFNalpha-dependent association of CrkL with Tyk-2 in intact cells. Two other Type I IFNs, IFNbeta and IFNomega, also induce tyrosine phosphorylation of CrkL, suggesting that the protein is involved in the signaling pathways of several different Type I IFNs. In the IFNalpha-sensitive U-266 and Daudi cell lines, CrkL interacts via its N terminus SH3 domain with the guanine exchange factor C3G that regulates activation of Rap-1, a small G-protein that exhibits tumor suppressor activity. Thus, tyrosine phosphorylation of CrkL links the functional Type I IFNR complex to the C3G-Rap-1 signaling cascade that mediates growth inhibitory responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374471     DOI: 10.1074/jbc.272.48.29991

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Molecular mechanisms in T helper phenotype development.

Authors:  J D Farrar; S H Ranganath; K M Murphy
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.

Authors:  Kenji Oritani; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma.

Authors:  Chia-Hung Liu; Tzu-Chi Chen; Gar-Yang Chau; Yi-Hua Jan; Chun-Houh Chen; Chun-Nan Hsu; Kuan-Ting Lin; Yue-Li Juang; Pei-Jung Lu; Hui-Chuan Cheng; Ming-Huang Chen; Chia-Fen Chang; Yu-Shan Ting; Cheng-Yan Kao; Michael Hsiao; Chi-Ying F Huang
Journal:  Mol Cell Proteomics       Date:  2013-02-08       Impact factor: 5.911

Review 4.  IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review.

Authors:  Vasiliki Galani; Michalis Kastamoulas; Anna Varouktsi; Evangeli Lampri; Antigoni Mitselou; Dimitrios L Arvanitis
Journal:  Clin Exp Med       Date:  2016-07-14       Impact factor: 3.984

5.  Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.

Authors:  Simrit Parmar; Jessica Smith; Antonella Sassano; Shahab Uddin; Efstratios Katsoulidis; Beata Majchrzak; Suman Kambhampati; Elizabeth A Eklund; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

6.  Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.

Authors:  Sonali Joshi; Bhumika Sharma; Surinder Kaur; Beata Majchrzak; Takeshi Ueda; Rikiro Fukunaga; Amit K Verma; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

7.  Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.

Authors:  Blazej Dolniak; Efstratios Katsoulidis; Nathalie Carayol; Jessica K Altman; Amanda J Redig; Martin S Tallman; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2008-02-25       Impact factor: 5.157

8.  IL-7-induced phosphorylation of the adaptor Crk-like and other targets.

Authors:  Francesca B Aiello; Tad Guszczynski; Wenqing Li; Julie A Hixon; Qiong Jiang; Deborah L Hodge; Tania Massignan; Chiara Di Lisio; Anand Merchant; Antonio D Procopio; Valentina Bonetto; Scott K Durum
Journal:  Cell Signal       Date:  2018-03-24       Impact factor: 4.315

9.  Conventional protein kinase C inhibition prevents alpha interferon-mediated hepatitis C virus replicon clearance by impairing STAT activation.

Authors:  Gian Maria Fimia; Cristina Evangelisti; Tonino Alonzi; Marta Romani; Federica Fratini; Giacomo Paonessa; Giuseppe Ippolito; Marco Tripodi; Mauro Piacentini
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Long-term pegylated interferon-alpha and its potential in the treatment of melanoma.

Authors:  Reinhard Dummer; Joanna Mangana
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.